- Health Canada DPD: OTIXAL (MEDEXUS PHARMACEUTICALS INC., DIN 02459655) · product monograph (PDF)
Links only. These regulators' terms do not clearly permit reproducing the documents, so no text is shown here. Check the Philippine package insert in the products table.
Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Skin and Skin Structure Infections US FDA label
Kidney dosing: Ciprofloxacin (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Usual dosing (label: CrCl >50).
- CrCl 30–59 mL/min
- Oral: CrCl >50, usual dosing; CrCl 30–50, 250 to 500 mg every 12 hours (label). IV: CrCl >30, usual dose (IV label).
- CrCl 15–29 mL/min
- Oral: CrCl 5–29, 250 to 500 mg every 18 hours (label); severe infection: a 750 mg unit dose may be given at these intervals with careful monitoring. IV: CrCl 5–29, 200 to 400 mg every 18 to 24 hours (IV label).
- CrCl <15 mL/min (not on dialysis)
- Oral: CrCl 5–29, 250 to 500 mg every 18 hours (label). IV: CrCl 5–29, 200 to 400 mg every 18 to 24 hours (IV label). Below 5 not on dialysis: not addressed; specialist input.
- Hemodialysis (intermittent)
- Oral: 250 to 500 mg every 24 hours, after dialysis (label). IV: dialysis not addressed in the IV label; specialist input.
- Peritoneal dialysis
- Oral: 250 to 500 mg every 24 hours (the label groups hemodialysis and peritoneal dialysis). IV: dialysis not addressed in the IV label; specialist input. For PD-associated peritonitis (ISPD 2022): intraperitoneal continuous maintenance 50 mg/L (no intermittent IP data); systemic oral 500–750 mg daily (750 mg twice daily for CCPD) (ISPD Table 6).
- CRRT
- Not in label. Published CRRT regimens: 200–400 mg IV every 8–12 hours by effluent rate (Li 2020); specialist input.
- Dialyzable? Minimal: less than 10% removed by hemodialysis or peritoneal dialysis (label).
- Monitoring Tendon rupture, QT prolongation, dysglycemia, central nervous system effects; crystalluria (keep hydrated).
From the Ciprofloxacin monograph (renalcarematters.com, reviewed).
Use: INDICATIONS AND USAGE SYNALAR ® Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses. US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Per ml otic solution: 3 mg/250 mcg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Ciprofloxacin + Fluocinolone acetonide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Cetraxal PlusCiprofloxacin (as hydrochloride) + Fluocinolone acetonide | 3 mg/250 mcg per mL Otic Solution (Ear Drops)White, opaque LDPE bottle with HDPE cap and fitted LDPE dropper x 10 mL (Box of 1's) | Rx | Laboratorios Salvat, S.A.Spain | Hyphens Pharma Philippines, Inc.Trader: Hyphens Pharma Pte. Ltd. | DR-XY45435 | Oct 11, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .